Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
Background With the advent of next generation integrase strand transfer inhibitors, the rates of virologic failure in treated subjects are expected to decrease. In this study, we analyzed the mutation patterns leading to virologic failure before and after starting integrase strand transfer inhibitor...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-05-01
|
| Series: | Antiviral Chemistry & Chemotherapy |
| Online Access: | https://doi.org/10.1177/2040206620927908 |